ABSTRACT
Introduction Despite a prevalence of 3-5% among adults, asymptomatic left ventricular systolic dysfunction (LVSD) remains underdiagnosed. There is a critical need for an accurate and widely accessible screening strategy for LVSD, given its association with preventable morbidity and premature mortality. A novel deep learning approach has demonstrated the ability to detect LVSD directly from ECG images, with retrospective validation across multiple institutions. There is a lack of prospective validation. In this pilot study, we evaluate the feasibility of screening and recruiting individuals for prospective echocardiography based on an image-based artificial intelligence (AI)-ECG algorithm applied to the ECG repository at a large academic medical center.
Research Methods and Analysis This is the protocol for a prospective cohort study in outpatient primary care clinics of the Yale New Haven Hospital (YNHH). Adult patients who have undergone a 12-lead ECG without subsequent echocardiogram as a part of routine clinical care within 90 days of the ECG will be identified in the electronic health record (EHR). The AI-ECG model for LVSD will be deployed to YNHH ECG repository to define the probability of LVSD, identifying 5 patients each with high and low probability of LVSD. After discussion with primary care physicians, and subsequent contact by the study team, screened participants will be invited for and undergo an echocardiogram. The study participants and the cardiologists conducting the echocardiograms will be blinded to the results of the AI-ECG screen. The analysis will focus on feasibility metrics: the proportion (i) of all patients undergoing ECGs who have high probability of LVSD without subsequent echocardiogram, (ii) of patients who agree to participate in the study, and (iii) that undergo an echocardiogram. A descriptive exploration of the comparison of the AI-ECG and echocardiogram results will also be reported.
Ethics and Dissemination All patient EHR data required for assessing eligibility and conducting the AI-ECG screening will be accessed through secure servers approved for protected health information. Potential participants will only be contacted after they have discussed the study information with their primary care physician. All participants will be required to provide written informed consent before participation and data will be deidentified prior to analysis. This study protocol has been approved by the Yale Institutional Review Board (Protocol Number: 2000034006) and has been registered at ClinicalTrials.gov (Identifier: NCT05630170). The results of the future validation study will be published in peer-reviewed journals and summaries will be provided to the study participants.
Competing Interest Statement
Dr. Khera receives research grant support, through Yale, from Bristol‐Myers Squibb and Novo Nordisk. He is a coinventor of U.S. Pending Patent Application No. 63/177,117, "Methods for neighborhood phenomapping for clinical trials", U.S. Provisional Patent Application No. 63/346,610, "Articles and methods for format independent detection of hidden cardiovascular disease from printed electrocardiographic images using deep learning", and U.S. Provisional Patent Application No. 63/428,569, "Articles and methods for detection of hidden cardiovascular disease from portable electrocardiographic signal data using deep learning". He is also a founder of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care. Dr. Oikonomou is a co-inventor of the U.S. Provisional Patent Application 63/177,117, a co-founder of Evidence2Health, and reports a consultancy and stock option agreement with Caristo Diagnostics Ltd (Oxford, U.K.), all unrelated to the current work. Dr. Wilson reports grant support from NIDDK R01DK113191, AHRQ R01HS027626 and research funding from AstraZeneca and Vifor Pharma that are not relevant to this manuscript. He also reports research funding from WHOOP, a wearable device company, that is relevant to this manuscript. Dr. Mortazavi reports receiving grants from the National Institute of Biomedical Imaging and Bioengineering, National Heart, Lung, and Blood Institute, US Food and Drug Administration, and the US Department of Defense Advanced Research Projects Agency outside the submitted work; in addition, Dr. Mortazavi has a pending patent on predictive models using electronic health records (US20180315507A1). Dr. Krumholz reports receiving expenses and/or personal fees from UnitedHealthcare, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, the Siegfried & Jensen law firm, the Arnold & Porter law firm, and the Martin Baughman law firm; being a co-founder of Refactor Health and Hugo Health; and being associated with contracts through Yale New Haven Hospital from the Centers for Medicare & Medicaid Services and through Yale University from Johnson & Johnson outside the submitted work. The remaining authors have no disclosures to report. The other authors do not report any disclosures.
Clinical Trial
NCT05630170
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Yale Institutional Review Boards granted approval for the study protocol and granted a waiver of HIPAA authorization for access to and use of protected health information (PHI) as described in the approved protocol for recruitment purposes only. Protocol number:2000034006
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
1. Updated the Introduction section to add two additional external validation site results. (Cedars Sinai Medical Center and ELSA-Brasil Study) 2. Updated the Study Duration section from January-April 2023 to January-July 2023 to better reflect the updated timeline for our study. 3. Updated the Study Design section to modify the high model predicted probability threshold from ≥80% to ≥10%. The ≥10% threshold was found to be optimal based on further analysis of retrospective data from Yale New Haven Hospital. Moreover, the patients with model predicted probability of ≥80% tended to be patients with established heart failure, precluding their eligibility in our study. No other sections were modified.
Data Availability
All data (excluding protected health information of the participants) produced in the present study will be available upon reasonable request to the authors.
